drugset / Trial / NCT00611130

Vigabatrin for Treatment of Cocaine Dependence

NCT00611130

Phase 2 Completed 186 enrolled Catalyst Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.

Timeline

Start
2008-01
Primary completion
2009-05
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Vigabatrin Small molecule 3000 mg

Indications